Abstract
The farnesoid X receptor (FXRα) is a metabolic nuclear receptor and bile acid sensor expressed in the liver and intestine. Physiological studies have shown that FXR.. exerts regulatory roles in bile acids, lipid and glucose homeostasis. FXR ligands of steroidal and non-steroidal structure have been described. Both ligand groups have shown limitations in preclinical studies regarding their absorption, metabolism, target interactions and intrinsic toxicity. Inhibition of bile acid synthesis and basolateral transporters in the liver as well as reduction of high density lipoprotein (HDL) in the plasma are the major unwanted effects seen with these ligands. Several FXRα modulators are currently being generated with the aim of targeting FXRα isoforms by exploiting the relative unselectivity of the ligand binding domain of the receptor. Structure- activity relationship studies have shown that FXRα could be activated by structurally different ligands and that receptor occupancy by these ligands generates different patterns of gene activation as a result of specific conformational changes of the receptor or differential dislodgement of co-repressor or recruitment of co-activators. Generation of modulators that selectively target specific FXRα responsive elements are an interesting strategy to overcome the limitations of currently available FXR ligands.
Current Medicinal Chemistry
Title: Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment
Volume: 17 Issue: 2
Author(s): S. Fiorucci, A. Mencarelli, E. Distrutti, G. Palladino and S. Cipriani
Affiliation:
Abstract: The farnesoid X receptor (FXRα) is a metabolic nuclear receptor and bile acid sensor expressed in the liver and intestine. Physiological studies have shown that FXR.. exerts regulatory roles in bile acids, lipid and glucose homeostasis. FXR ligands of steroidal and non-steroidal structure have been described. Both ligand groups have shown limitations in preclinical studies regarding their absorption, metabolism, target interactions and intrinsic toxicity. Inhibition of bile acid synthesis and basolateral transporters in the liver as well as reduction of high density lipoprotein (HDL) in the plasma are the major unwanted effects seen with these ligands. Several FXRα modulators are currently being generated with the aim of targeting FXRα isoforms by exploiting the relative unselectivity of the ligand binding domain of the receptor. Structure- activity relationship studies have shown that FXRα could be activated by structurally different ligands and that receptor occupancy by these ligands generates different patterns of gene activation as a result of specific conformational changes of the receptor or differential dislodgement of co-repressor or recruitment of co-activators. Generation of modulators that selectively target specific FXRα responsive elements are an interesting strategy to overcome the limitations of currently available FXR ligands.
Export Options
About this article
Cite this article as:
Fiorucci S., Mencarelli A., Distrutti E., Palladino G. and Cipriani S., Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment, Current Medicinal Chemistry 2010; 17 (2) . https://dx.doi.org/10.2174/092986710790112666
DOI https://dx.doi.org/10.2174/092986710790112666 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Dysfunction and Nutritional Compounds in Early Type 1 Diabetes
Current Diabetes Reviews Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
Current Molecular Medicine The Menstrual Cycle and Drug Metabolism
Current Drug Metabolism Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Diabetes and Obesity in Pregnancy: From Patients to Molecular Mechanisms
Current Vascular Pharmacology Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review
Current Diabetes Reviews Diagnosis of Gout: Considering Clinical and Research Settings
Current Rheumatology Reviews Impact of Pre-existing Kidney Dysfunction on Outcomes Following Transcatheter Aortic Valve Replacement
Current Cardiology Reviews Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Crucial Role of PDX-1 in Pancreas Development, β-Cell Differentiation, and Induction of Surrogate β-Cells
Current Medicinal Chemistry The Correlated Factors of Serum CA19-9 Levels in Diabetic Patients
Current Diabetes Reviews Exercise and Cardiac Preconditioning Against Ischemia Reperfusion Injury
Current Cardiology Reviews Effect on Adipose Tissue of Diabetic Mice Supplemented with n-3 Fatty Acids Extracted from Microalgae
Endocrine, Metabolic & Immune Disorders - Drug Targets Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Biomarkers of Oxidative Stress and the Relationship to Cigarette Smoking
Mini-Reviews in Organic Chemistry Enterobacteriaceae that Produce Extended-spectrum β -lactamases and AmpC β -lactamases in the Community: The Tip of the Iceberg?
Current Pharmaceutical Design